A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either capsule or oral liquid formulation, as adjunctive therapy in pediatric subjects 4 to 16 years of age with partial onset seizures.
Inclusion Criteria:
Exclusion Criteria:
Lexington, Kentucky 40536, United States
Brno - Cerna Pole, 613 00, Czechia
Pavia, 27100, Italy
Wroclaw, 54-049, Poland
Izmir, Bornova 35100, Turkey (Türkiye)
Trabzon, Farabi 61080, Turkey (Türkiye)
Izmir, Konak 35210, Turkey (Türkiye)
Dnipropetrovsk, 49100, Ukraine
Kharkiv, 61068, Ukraine
Odesa, 65031, Ukraine
S. Oleksandrivka, 67513, Ukraine